Skip to main content

Table 1 Baseline characteristics

From: High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

  N = 243
Median Age (range) – yr. 48 (14–77)
Sex – no. (%)
  Male 133 (55)
  Female 110 (45)
Primary Site – no. (%)
 Cutaneous 188 (77)
  H&N 34 (14)
  LE 38 (16)
  UE 29 (12)
  Breast 1 (<1)
  Trunk – anterior/posterior 74 (30)
  Unknown 12 (5)
 Mucosal 14 (6)
  GI - anorectal 3 (1)
  Aerodigestive 3 (1)
  Urethral 1 (<1)
  Vulva 7 (3)
 Unknown 24 (10)
 Uveal (choroid) 16 (7)
 Other (orbit) 1 (<1)
Metastatic status prior to HD IL-2 – no. (%)
 Skin, subcutaneous, LN (M1a) 43 (18)
 Lung (M1b) 58 (24)
 Non-lung visceral (M1c non-CNS) 99 (41)
 CNS (M1c CNS) 43 (18)
LDH – no. (%)
 Normal 106 (44)
 Abnormal 137 (56)
  1xULN-2xULN 74 (30)
   > 2xULN 63 (26)
Protocol – no. (%)
 Standard of care (SOC) 193 (79)
 HD IL-2/temozolomide 30 (12)
 HD IL-2+/− ziv-aflibercept (HD IL-2 alone) 20 (8)
Line of therapy – no. (%)
 1st line 114 (47)
 2nd line 83 (34)
 3rd line or subsequent line 46 (19)
Pre-HD IL-2 therapies* – no. (%)
 CTLA-4 inhibitor 20 (8)
 PD-1 inhibitor 2 (1)
 Other immunotherapies (including biochemotherapy) 73 (30)
 BRAFi/MEKi target therapy 3 (1)
 Other targeted therapy 13 (5)
 Chemotherapy 54 (22)
Post-progression therapies* – no. (%)
 CTLA-4 inhibitor 29 (12)
 PD-1 inhibitor 11 (5)
 Other immunotherapies (including biochemotherapy) 29 (12)
 BRAFi/MEKi target therapy 12 (5)
 Other targeted therapy 5 (2)
 Chemotherapy 43 (18)
  1. *These categories are not mutually exclusive or exhaustive